Combination treatment strategies with PD-(L)1 and CTLA-4 ICB antibodies have shown a higher clinical efficacy than either agent alone (5, 66–69) and are currently approved in melanoma and NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.